• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Therapeutic system in the form of a skin patch that administers clonidine transdermally in an initial priming dose of 10 to 300 mcg/cm2 of skin that brings the concentration of clonidine in the blood to a level sufficient to elicit alpha-adrenergic stimulation without intolerable side effects, followed by a substantially constant continuous dosage in the range of 0.1 to 100 mcg/hr that maintains said level. The system is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-clonidine reservoir lamina that is the source of the clonidine for the continuous constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-clonidine contact adhesive layer that is the source of the clonidine for the priming dose and the means by which the system is attached to the skin.
    公开号:SU1005650A3
    申请号:SU782638599
    申请日:1978-07-11
    公开日:1983-03-15
    发明作者:Кумар Хандразекаран Сантош；Дарда Зигфрид；С.Мишаэлз Элэн；В.Клири Гэри
    申请人:Алза Корпорейшн (Фирма)；К.Х.Берингер Зон (Фирма)；
    IPC主号:
    专利说明:

    (54) MEDICAL PLASTER PLATFORMER The invention relates to medicine, namely to patches for transdermal applications. The known prolongator for a polyphenidine-based medical plaster. However, the well-known prolongator does not both maintain the recoil constants of clonquin, which reduces the effectiveness of the treatment. The aim of the invention is to increase the rate of return of clonidine. This goal is achieved by the fact that the prolongator for a medical plastir-clonidine based on polyolefins as a polyolefin contains a mixture of low molecular weight and high molecular weight polyisobutenes and additionally contains mineral oil with the following ratio kcm1C) nnthe,%; Mineral oil 65-35
    权利要求:
    Claims (3)
    [1]
    KLONIDINA Polyisobutenes are taken in a ratio of 4–4: 1, with low molecular weight oliisobutene having a molar weight of 35OOOO50OOO, and high molecular weight popiisoene - 1OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPOOOOOOOHOOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOROOLOOHOOHOOHOOHOOHYLENE The proponator contains mineral aslo with a viscosity of 1O-1OO cP. at. The drawing shows the patch with the proposed prolongator, General view. Plaster 1 consists of five layers. Bulk layer 2 basically does not allow Clonndin to pass through. Its outer surface 3 forms the surface of the patch 1. The top layer 2 is a hardening shell that prevents volatilization of volatile components from the patch, and is made of a polymer film and metal foil, such as aluminum. Under layer 2, there is a reserve layer of 4-clonidine containing from 1 to 6 mg of clonidine, the insoluble part of which has the form of particles 5, which are dispersed in mineral oil with a viscosity of 1O-1OO cp at 25 ° C in a mixture of polybranes consisting of low-pulp and molar Beccevi 35000-50000 and from vysokopekpekup. The molar weight of polyobromine is lOdOOOO-1500000, taken at an oot ratio of 1: 4 to 4: 1, and the ratio of components is, wt.%: A mixture of low molecular weight and high molecular weight half isobutene 35 65 Mineral oil 35-65 Mineral oil serves as a carrier of clonidine . The next layer of plaster 1 is a microporous membrane 6, the pores of which are filled with mineral maelstl. The membrane 6 controls the feed rate of clonidine and layer 4, while the speed is adjusted so that after applying the patch to the skin the clonidy comes from layer 4 with a constant speed ranging from 0.1 to 100 µg / h, while the diffusion depends on the viscosity mineral oil and decreases with the increase of the latter. Membrane 6 is made with permeability from 0.1 to 0.85, curvature from 1 to 10, and thickness 10 to 10 cm from polymers. Under the membrane 6 there is a contact adhesive layer 7 containing 10-ZOOmk clonidine per cm of effective surface. Clonidine is absorbed into bed 7 as the main dose. Sung 7 has the same composition as layer 4 and is an agent applied to the skin. Before use, patch 1 of the protective layer 8, which is inert with respect to layer 7, is removed. Prolongator obtained as follows. By homogeneous mixing, a mixture of low molecular weight and high molecular weight polyisobutenes and mineral oil is obtained at the following ratio of components,%: A mixture of low molecular weight and high molecular weight polyisobutenes 35-5 Mineral oil 35-65 At the same time, polyisobutene is taken in combination 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4. , while the low molecular weight polyisobutene has a pooled weight of 350OO-50OOO, and high molecular weight polyisobutene has a pOOHE of 1500OOO, and mineral oil is used with a viscosity of 10 -10 O cP at Example 1.N-hexane to add 2.0 g of finely porous clone cc and 65 g of mineral oil with viscosity 20 centipoise at and over 10 min was adjusted until homogeneous. Then, 7.0 g of n-molecular polyisobutene with 4OOOO molar and 20.0 g of high molecular-weight polyisobutene with molar 1OOOOOO are added to the resulting solution, and the mixture is stirred until all polyolefia are completely dissolved. The resulting mixture is processed into a plaster by pouring it onto a polyethylene terephthalate film coated with aluminum foil 100 µm thick. After drying, it forms a layer of proliferating action with a thickness of 50 µm, which is coated with a microporous polypropylene film and then additionally applied with a siliconizing aluminum foil as a removable coating. Example 2. From 2.9% by weight of 2,6-dichloro-N -2-imidazolidinylide1-benzamine, 10.4% by weight of mineral oil (10 cP at 25 ° C) and 75% by weight of heptane, a slurry is prepared. Then it is at 50 ОО1ОООО rpm 1Х) Mogenised for. 10 min. A mixture of 5.2 wt.% Of high molecular weight polyisobutenes with a molar weight of 1 20OOOO with 6.5 wt.% Of low molecular weight 1 polyisobutenes with a molar weight of 35,000 is added to the homogenized slurry and slowly stirred until the beveamine particles are suspended. and polyeobutenes do not dissolve. The resulting mixture is poured onto a 10O µm thick supporting film made of aluminum foil-coated polyethylene terephthalate, then it is dried overnight and placed for 15 minutes in an oven at 0 ° C to form a benzamine layer approximately 5O µm thick. The combination of the contact adhesive layer and the removable protective layer is prepared in the same way, and a similarly prepared mixture containing, in wt%: bevzamin 0.9; mineral suit 11.4; heptane 75; the high molecular weight oliisobutenes 5.7 and the low molecular weight potbumens 7 are poured onto a 125 μm thick film coated with silicone and aluminum and supported on a polyethylene film of polyethylene terephthalate. The thickness of the entire combination is approximately 175 microns. Then, the above described combination of a contact adhesive layer and a removable protective layer is layered on one side of a microporous mineral oil-saturated polypropylene membrane having a thickness of 2–5 μm, and a homombium from the top layer and a reserve layer of benzamine is layered on the opposite side of the membrane. Then, round plasters with a size of 1 D cm are punched from the obtained layer. The proposed prolongator transdermally feeds the closhes into the blood circulation and causes alpha-adrenergic stimulation without unacceptable side effects, such as severe dry mouth or unconsciousness, which is achieved by clotting the blood into the blood with a constant cause of the alpha-adrenal syndrome. stimulus. was going at a rate that may be preceded by an initial dose. Claims 1. prolongatory for medical plao sput nklonidina based poliolefvna, characterized in that, with increasing persistence Pellew recoil kdonidina as polyolefin he ooavr INH-molecular mixture nvzkomolekul tr vyookomolekul rzhgo popiizobutevov and additionally contains:;. Sieves mineralaee oil Scht the following ratio of components,%: A mixture of low molecular weight and high molecular weight of the floor of non-butenes 35 65 Mineral oil 35-65
    [2]
    2. Prolongator pop. 1, differing from the fact that the half-butenes are taken in a ratio of -1: 4 4: 1;
    [3]
    3. The proponent according to claim 1, about t l n h a y y and with the fact that it contains its own oil with bone Yu-1OO cP at a temperature. Sources of information taken more attention in the examination 1. US Patent No. 3797494, cl. 128-268, 197O.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1005650A3|1983-03-15|Slow-release agent for medicinal clonidine plaster
    US4031894A|1977-06-28|Bandage for transdermally administering scopolamine to prevent nausea
    FI79467B|1989-09-29|NYTT BANDAGE FOER ADMINISTRERING AV ETT CEILINGS.
    US4262003A|1981-04-14|Method and therapeutic system for administering scopolamine transdermally
    US5306503A|1994-04-26|Patch with a high content of softening ingredients
    JP2749832B2|1998-05-13|Improved transdermal drug delivery device
    JP2511472B2|1996-06-26|Improved transdermal delivery device with velocity control adhesive
    US4573995A|1986-03-04|Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
    DK175580B1|2004-12-13|Transdermal absorption dose unit for narcotic analgesics and antagonists
    JP4806162B2|2011-11-02|Cement for treating dysfunction and disease of nail growth
    IE63498B1|1995-05-03|Multilayer Plaster
    JP2019525932A|2019-09-12|Transdermal delivery of amine drugs facilitated by in situ conversion of sodium bicarbonate
    CA2550704C|2014-05-13|Nicotine transdermal delivery system
    US5714162A|1998-02-03|Scopolamine patch
    US4436741A|1984-03-13|Method for administering scopolamine transdermally
    EP0144486A2|1985-06-19|Controlled-release drugsystem and process for preparing it
    CA2403949C|2008-09-16|Transdermal therapeutic system for the delivery of lerisetron
    AU709288B2|1999-08-26|Transdermal therapeutic system | for the administration of drugs for treatment of drug dependency or drug addiction
    HU206991B|1993-03-01|Method for producing transdermal system advantageously plaster suitable for gradual feeding the active ingredient
    US4826686A|1989-05-02|Therapeutic system
    US4931281A|1990-06-05|Laminar structure for administering a chemical at a controlled release rate
    JP2524190B2|1996-08-14|Adhesive tape formulation containing clonidine
    HU0003480A2|2001-02-28|Transdermal therapeutic system containing the active substance scopolamine base
    JP2001514226A5|2006-06-22|
    JPH07106978B2|1995-11-15|Complex patch preparation
    同族专利:
    公开号 | 公开日
    FI772754A|1979-01-13|
    AT362884B|1981-06-25|
    CH646876A5|1984-12-28|
    CA1089362A|1980-11-11|
    PL113984B1|1981-01-31|
    GB1577259A|1980-10-22|
    ES472073A1|1979-03-16|
    BG29866A3|1981-02-16|
    NZ185000A|1979-08-31|
    NO772955L|1979-01-15|
    AU2846277A|1979-03-08|
    DE2755661A1|1979-01-25|
    AU512328B2|1980-10-02|
    AR218037A1|1980-05-15|
    ATA905877A|1980-11-15|
    IE46069B1|1983-02-09|
    JPS5420129A|1979-02-15|
    JPS6214526B2|1987-04-02|
    LU78845A1|1979-09-06|
    DK159375B|1990-10-08|
    DK387777A|1979-01-13|
    US4201211A|1980-05-06|
    BE862585A|1978-05-02|
    GR61591B|1978-12-02|
    PT67128B|1979-03-16|
    ZA775848B|1978-08-30|
    DD135566A5|1979-05-16|
    PH16059A|1983-06-09|
    PL204853A1|1979-09-10|
    YU166578A|1985-03-20|
    YU41594B|1987-10-31|
    IT1104643B|1985-10-21|
    DE2755661C2|1986-05-22|
    DK159375C|1991-03-18|
    HU179397B|1982-10-28|
    FR2397190A1|1979-02-09|
    PT67128A|1977-11-01|
    IL52839A|1979-09-30|
    FR2397190B1|1982-10-15|
    SE7709731L|1979-01-13|
    ES245891U|1980-06-01|
    NL7710213A|1979-01-16|
    IE46069L|1979-01-12|
    IL52839D0|1977-10-31|
    NL189800B|1993-03-01|
    NL189800C|1993-08-02|
    RO75336A|1980-12-30|
    ES245891Y|1980-12-16|
    CS216917B2|1982-12-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3190802A|1961-10-09|1965-06-22|Boehringer Sohn Ingelheim|Shaving composition and method of using same|
    US3236857A|1961-10-09|1966-02-22|Boehringer Sohn Ingelheim|2--1, 3-diazacyclopentene- substitution products|
    US3854480A|1969-04-01|1974-12-17|Alza Corp|Drug-delivery system|
    US3797494A|1969-04-01|1974-03-19|Alza Corp|Bandage for the administration of drug by controlled metering through microporous materials|
    US3598122B1|1969-04-01|1982-11-23|
    DE1928798C3|1969-06-06|1981-06-11|C.H. Boehringer Sohn, 6507 Ingelheim|Use of 2- -1,3-diazacyclopenten- |
    US3731683A|1971-06-04|1973-05-08|Alza Corp|Bandage for the controlled metering of topical drugs to the skin|
    US3742951B1|1971-08-09|1982-11-23|
    AR207805A1|1975-02-06|1976-10-29|Alza Corp|SUITABLE SUBSTRATE TO FORM DRESSINGS FOR THE CONTINUOUS DISPENSATION OF BASE SCCOPOLAMINE BY TRANSDERMAL ROUTE|
    US3972995A|1975-04-14|1976-08-03|American Home Products Corporation|Dosage form|
    US4031894A|1975-12-08|1977-06-28|Alza Corporation|Bandage for transdermally administering scopolamine to prevent nausea|DE2920500A1|1979-05-21|1980-11-27|Boehringer Sohn Ingelheim|PHARMACEUTICAL PREPARATION IN THE FORM OF A POLYACRYLATE FILM|
    JPS57134413A|1981-02-14|1982-08-19|Nitto Electric Ind Co Ltd|Percutaneous absorbable drug and product containing the same|
    JPS6059207B2|1981-03-13|1985-12-24|Nitto Electric Ind Co|
    JPS57150503U|1981-03-17|1982-09-21|
    US4725272A|1981-06-29|1988-02-16|Alza Corporation|Novel bandage for administering beneficial drug|
    GB2105990B|1981-08-27|1985-06-19|Nitto Electric Ind Co|Adhesive skin patches|
    US5310559A|1982-09-01|1994-05-10|Hercon Laboratories Corporation|Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer|
    JPH046168B2|1982-11-08|1992-02-05|Sekisui Chemical Co Ltd|
    JPS5984817A|1982-11-08|1984-05-16|Sekisui Chem Co Ltd|Pharmaceutical for prolonged release of chemical|
    JPS5984814A|1982-11-08|1984-05-16|Sekisui Chem Co Ltd|Pharmaceutical for prolonged release of chemical|
    GB2133284A|1983-01-07|1984-07-25|English Grains Limited|Resilient pharmaceutical unit for treating mouth ulcers|
    US4564364A|1983-05-26|1986-01-14|Alza Corporation|Active agent dispenser|
    FR2548021B1|1983-06-29|1986-02-28|Dick P R|PROLONGED AND CONTINUOUS DERMAL PHARMACEUTICAL COMPOSITIONS BASED ON ESSENTIAL FATTY ACIDS|
    DE3344691A1|1983-12-10|1985-06-20|Bayer Ag, 5090 Leverkusen|ACTIVE GAS EXHAUST SYSTEMS|
    DE3347277A1|1983-12-28|1985-07-11|Bayer Ag, 5090 Leverkusen|ACTIVE SUBSTANCE DELIVERY SYSTEMS|
    JPH0425928B2|1984-03-05|1992-05-06|Nitto Denko Corp|
    GB2156215B|1984-03-05|1988-03-02|Nitto Electric Ind Co|Percutaneous absorption type adhesive pharmaceutical preparation|
    DE3409079A1|1984-03-13|1985-09-19|Bayer Ag, 5090 Leverkusen|MEDICAL PLASTER|
    US4725439A|1984-06-29|1988-02-16|Alza Corporation|Transdermal drug delivery device|
    US4704282A|1984-06-29|1987-11-03|Alza Corporation|Transdermal therapeutic system having improved delivery characteristics|
    US4655768A|1984-07-06|1987-04-07|Avery International Corporation|Bandage for sustained delivery of drugs|
    US4588580B2|1984-07-23|1999-02-16|Alaz Corp|Transdermal administration of fentanyl and device therefor|
    US4532244A|1984-09-06|1985-07-30|Innes Margaret N|Method of treating migraine headaches|
    US4568343A|1984-10-09|1986-02-04|Alza Corporation|Skin permeation enhancer compositions|
    US4573995A|1984-10-09|1986-03-04|Alza Corporation|Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine|
    AT95430T|1984-12-22|1993-10-15|Sanol Arznei Schwarz Gmbh|ACTIVE PLASTER.|
    US4615699A|1985-05-03|1986-10-07|Alza Corporation|Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes|
    DE3518707A1|1985-05-24|1986-11-27|Beiersdorf Ag, 2000 Hamburg|NITRO PLASTER|
    EP0252076A1|1985-12-12|1988-01-13|Flexcon Company, Inc.|Transdermal methods and adhesives|
    US4765974A|1985-12-24|1988-08-23|Nitto Electric Industrial Co., Ltd.|Preparation for percutaneous administration|
    US5204339A|1986-01-31|1993-04-20|Whitby Research, Inc.|Penetration enhancers for transdermal delivery of systemic agents|
    US4886545A|1986-01-31|1989-12-12|Nelson Research & Development Company|Compositions comprising 1-substituted azacycloalkanes and their uses|
    EP0249343B1|1986-06-13|1992-01-08|Alza Corporation|Moisture activation of transdermal drug delivery system|
    US4908027A|1986-09-12|1990-03-13|Alza Corporation|Subsaturated transdermal therapeutic system having improved release characteristics|
    US5344656A|1986-09-12|1994-09-06|Alza Corporation|Subsaturated transdermal therapeutic system having improved release characteristics|
    US5227157A|1986-10-14|1993-07-13|Board Of Regents, The University Of Texas System|Delivery of therapeutic agents|
    AU610839B2|1986-11-07|1991-05-30|Purepac, Inc|Transdermal administration of amines|
    US4917688A|1987-01-14|1990-04-17|Nelson Research & Development Co.|Bandage for transdermal delivery of systemically-active drug|
    US4830856A|1987-01-27|1989-05-16|Peppers James M|Chelation product|
    US4920101A|1987-09-30|1990-04-24|Nelson Research & Development Co.|Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes|
    US4879275A|1987-09-30|1989-11-07|Nelson Research & Development Co.|Penetration enhancers for transdermal delivery of systemic agent|
    US4781924A|1987-11-09|1988-11-01|Alza Corporation|Transdermal drug delivery device|
    US4906475A|1988-02-16|1990-03-06|Paco Pharmaceutical Services|Estradiol transdermal delivery system|
    JPH02149514A|1988-04-06|1990-06-08|Nitto Denko Corp|Material for medicine|
    NL8801445A|1988-06-06|1990-01-02|Dow Chemical Nederland|COEXTRUDED SYNTHETIC RESIN STRUCTURES AND METHOD FOR MANUFACTURING IT.|
    US5004610A|1988-06-14|1991-04-02|Alza Corporation|Subsaturated nicotine transdermal therapeutic system|
    US5026556A|1988-11-10|1991-06-25|Norwich Eaton Pharmaceuticals, Inc.|Compositions for the transdermal delivery of pharmaceutical actives|
    US5324521A|1989-12-18|1994-06-28|Dermamed|Systems for transdermal administration of medicaments|
    US5332577A|1988-12-27|1994-07-26|Dermamed|Transdermal administration to humans and animals|
    US5241925A|1988-12-27|1993-09-07|Dermamed|Apparatus and techniques for administering veterinary medicaments|
    US6559186B1|1990-02-26|2003-05-06|Arc 1, Inc.|Compositions and methods of treatment of sympathetically maintained pain|
    US5447947A|1990-02-26|1995-09-05|Arc 1|Compositions and methods of treatment of sympathetically maintained pain|
    US5070084A|1990-02-26|1991-12-03|Campbell James N|Treatment of sympathetically maintained pain|
    US5508038A|1990-04-16|1996-04-16|Alza Corporation|Polyisobutylene adhesives for transdermal devices|
    US5512292A|1990-10-29|1996-04-30|Alza Corporation|Transdermal contraceptive formulations methods and devices|
    US5402777A|1991-06-28|1995-04-04|Alza Corporation|Methods and devices for facilitated non-invasive oxygen monitoring|
    IT1251469B|1991-07-15|1995-05-15|Zambon Spa|TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF DRUGS WITH BRONCODILATING ACTIVITY.|
    CA2116036A1|1991-10-18|1993-04-29|F. Eugene Yates|Device for the transdermal administration of melatonin|
    US5900250A|1992-05-13|1999-05-04|Alza Corporation|Monoglyceride/lactate ester permeation enhancer for oxybutnin|
    NZ252598A|1992-05-13|1997-01-29|Alza Corp|Device for the transdermal administration of oxybutynincomprising a backing material, drug reservoir having a permeation enhancer and means of contact with the skin|
    US5451407A|1993-06-21|1995-09-19|Alza Corporation|Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug|
    AU7396294A|1993-06-25|1995-01-24|Alza Corporation|Incorporating poly-n-vinyl amide in a transdermal system|
    CA2167526A1|1993-09-29|1995-04-06|Lina Tormen Taskovich|Monoglyceride/lactate ester permeation enhancer|
    US5484607A|1993-10-13|1996-01-16|Horacek; H. Joseph|Extended release clonidine formulation|
    CN1078460C|1995-03-23|2002-01-30|北京三九克莱斯瑞控释药业有限公司|Preparing method for program-controlled skin permeable plaster|
    US5662928A|1995-04-21|1997-09-02|Ciba-Geigy Corporation|Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system|
    US6572879B1|1995-06-07|2003-06-03|Alza Corporation|Formulations for transdermal delivery of pergolide|
    DE19527925C2|1995-07-29|1997-07-03|Lohmann Therapie Syst Lts|Transdermal therapeutic system with a release agent-coated protective layer|
    CA2182851A1|1995-08-15|1997-02-16|August Masaru Watanabe|Method for treating substance abuse withdrawal|
    US6238700B1|1995-12-01|2001-05-29|Alza Corporation|Method for preventing crystal formation in a dispersion of a liquid in a matrix|
    ES2162124T3|1995-12-01|2001-12-16|Alza Corp|IMPROVED METHOD TO AVOID CRYSTAL FORMATION IN A DISPERSION OF A LIQUID IN A MATRIX.|
    AUPN814496A0|1996-02-19|1996-03-14|Monash University|Dermal penetration enhancer|
    US7094422B2|1996-02-19|2006-08-22|Acrux Dds Pty Ltd.|Topical delivery of antifungal agents|
    US5869089A|1996-03-21|1999-02-09|China-America Technology Corp. |Manufacturing method of programmable transdermal therapeutic system|
    US6007837A|1996-07-03|1999-12-28|Alza Corporation|Drug delivery devices and process of manufacture|
    US6512010B1|1996-07-15|2003-01-28|Alza Corporation|Formulations for the administration of fluoxetine|
    US6203817B1|1997-02-19|2001-03-20|Alza Corporation|Reduction of skin reactions caused by transdermal drug delivery|
    US5985317A|1996-09-06|1999-11-16|Theratech, Inc.|Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents|
    GB9711032D0|1997-05-30|1997-07-23|Johnson Matthey Plc|Compound as a stimulant for the central nervous system|
    US6174545B1|1997-07-01|2001-01-16|Alza Corporation|Drug delivery devices and process of manufacture|
    US5948433A|1997-08-21|1999-09-07|Bertek, Inc.|Transdermal patch|
    US6660295B2|1997-09-30|2003-12-09|Alza Corporation|Transdermal drug delivery device package with improved drug stability|
    CN100388916C|1997-12-22|2008-05-21|阿尔扎有限公司|Rate controlling membranes for controlled drug delivery device|
    US6699497B1|1998-07-24|2004-03-02|Alza Corporation|Formulations for the transdermal administration of fenoldopam|
    US6348210B1|1998-11-13|2002-02-19|Alza Corporation|Methods for transdermal drug administration|
    PT1140039E|1998-12-18|2010-02-03|Alza Corp|Transparent transdermal nicotine delivery devices|
    PT1163019E|1999-03-25|2007-12-06|Metabolix Inc|Medical devices and applications of polyhydroxyalkanoate polymers|
    WO2001015671A2|1999-08-30|2001-03-08|Tepha, Inc.|Flushable disposable polymeric products|
    US20040258742A1|2003-04-11|2004-12-23|Van Osdol William Woodson|Transdermal administration of N--N'--N'-methyl guanidines|
    AT344226T|2000-02-16|2006-11-15|Brigham & Womens Hospital|ASPIRIN-RELATED LIPID MEDIATORS|
    US7179483B2|2000-04-26|2007-02-20|Watson Pharmaceuticals, Inc.|Compositions and methods for transdermal oxybutynin therapy|
    WO2003032983A1|2001-06-05|2003-04-24|Ronald Aung-Din|Transdermal migraine therapy|
    US7030159B2|2001-12-18|2006-04-18|The Brigham And Women's Hospital, Inc.|Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs|
    US8481772B2|2002-04-01|2013-07-09|University Of Southern California|Trihydroxy polyunsaturated eicosanoid derivatives|
    US7902257B2|2002-04-01|2011-03-08|University Of Southern California|Trihydroxy polyunsaturated eicosanoid|
    AR033748A1|2002-05-15|2004-01-07|Thalas Group Inc|A DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES THAT INCLUDES TWO SUPERPOSED ADHESIVE LAYERS AND A PROCEDURE TO PREPARE IT|
    US7759395B2|2002-08-12|2010-07-20|The Brigham And Women's Hospital, Inc.|Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma|
    DE60330154D1|2002-08-12|2009-12-31|Brigham & Womens Hospital|RESOLVINE: BIOTEMPLATE FOR THE IMPLEMENTATION OF THERAPEUTIC APPLICATIONS|
    WO2004078143A2|2003-03-05|2004-09-16|The Brigham And Women's Hospital Inc.|Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs|
    ES2819189T3|2003-05-08|2021-04-15|Tepha Inc|Polyhydroxyalkanoate Medical Fibers and Fabrics|
    US8410102B2|2003-05-27|2013-04-02|Galderma Laboratories Inc.|Methods and compositions for treating or preventing erythema|
    US7439241B2|2003-05-27|2008-10-21|Galderma Laboratories, Inc.|Compounds, formulations, and methods for treating or preventing rosacea|
    US7014630B2|2003-06-18|2006-03-21|Oxyband Technologies, Inc.|Tissue dressing having gas reservoir|
    US20060200100A1|2003-06-18|2006-09-07|Rosati Coni F|Method and apparatus for supplying gas to an area|
    US20070065463A1|2003-06-20|2007-03-22|Ronald Aung-Din|Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions|
    CA2531833C|2003-07-08|2009-10-20|Tepha, Inc.|Poly-4-hydroxybutyrate matrices for sustained drug delivery|
    US20050020600A1|2003-07-23|2005-01-27|Scherer Warren J.|Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists|
    WO2005020825A1|2003-08-22|2005-03-10|Tepha, Inc.|Polyhydroxyalkanoate nerve regeneration devices|
    TWI239252B|2003-12-31|2005-09-11|Ind Tech Res Inst|A patch and the manufacturing method of the same|
    US20050238589A1|2004-04-14|2005-10-27|Van Dyke Thomas E|Methods and compositions for preventing or treating periodontal diseases|
    EP1747033A1|2004-04-30|2007-01-31|Burrell E. Clawson|Apparatus and methods for isolating human body areas for localized cooling|
    US7611628B1|2004-05-13|2009-11-03|University Of Kentucky Research Foundation|Aligned nanotubule membranes|
    WO2006015276A2|2004-08-03|2006-02-09|Tepha, Inc.|Non-curling polyhydroxyalkanoate sutures|
    ES2385386T3|2004-10-21|2012-07-24|Durect Corporation|Transdermal Administration Systems|
    US8252320B2|2004-10-21|2012-08-28|Durect Corporation|Transdermal delivery system for sufentanil|
    CA2596283C|2005-01-28|2011-11-01|Tepha, Inc.|Embolization using poly-4-hydroxybutyrate particles|
    AU2006294581B2|2005-09-27|2011-11-03|Tissuetech, Inc.|Amniotic membrane preparations and purified compositions and methods of use|
    US8187639B2|2005-09-27|2012-05-29|Tissue Tech, Inc.|Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment|
    US8273792B2|2005-10-03|2012-09-25|The Brigham And Women's Hospital, Inc.|Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers|
    US8026266B2|2005-11-08|2011-09-27|Arcion Therapeutics, Inc.|Treatment of length dependent neuropathy|
    US7888422B2|2005-11-09|2011-02-15|Mylan Technologies Inc.|Long-wearing removable pressure sensitive adhesive|
    EP1954291A1|2005-11-18|2008-08-13|Trustees Of Boston University|Treatment and prevention of bone loss using resolvins|
    NZ568700A|2005-11-28|2012-03-30|Marinus Pharmaceuticals|Solid stabilized particulate formulations comprising ganaxolone|
    US8518926B2|2006-04-10|2013-08-27|Knopp Neurosciences, Inc.|Compositions and methods of using -pramipexole|
    PL2026803T3|2006-05-16|2012-05-31|Knopp Neurosciences Inc|Compositions of r and s pramipexole and methods of using the same|
    US8524695B2|2006-12-14|2013-09-03|Knopp Neurosciences, Inc.|Modified release formulations of -4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same|
    US20070259930A1|2006-04-10|2007-11-08|Knopp Neurosciences, Inc.|Compositions and methods of using r pramipexole|
    WO2008021368A2|2006-08-11|2008-02-21|The Johns Hopkins University|Compositions and methods for neuroprotection|
    PT2526933E|2006-09-22|2015-06-23|Pharmacyclics Inc|Inhibitors of bruton's tyrosine kinase|
    KR20090091321A|2006-11-28|2009-08-27|마리누스 파마슈티컬스|Nanoparticulate formulations and methods for the making and use thereof|
    US7943683B2|2006-12-01|2011-05-17|Tepha, Inc.|Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers|
    US20080152709A1|2006-12-22|2008-06-26|Drugtech Corporation|Clonidine composition and method of use|
    WO2008103818A1|2007-02-21|2008-08-28|University Of Louisville Research Foundation|Therapeutic cotinine compositions|
    US8519148B2|2007-03-14|2013-08-27|Knopp Neurosciences, Inc.|Synthesis of chirally purified substituted benzothiazole diamines|
    CA2682200C|2007-03-19|2015-01-13|Vita Sciences, Llc|Transdermal patch and method for delivery of vitamin b12|
    US20100172991A1|2007-06-08|2010-07-08|Henry Joseph Horacek|Extended Release Formulation and Methods of Treating Adrenergic Dysregulation|
    EP2155170A2|2007-06-08|2010-02-24|Addrenex Pharmaceuticals, Inc.|Extended release formulation and method of treating adrenergic dysregulation|
    US9017301B2|2007-09-04|2015-04-28|Mylan Technologies, Inc.|Transdermal drug delivery systems comprising a coated release liner|
    CN101854933A|2007-09-10|2010-10-06|钙医学公司|Regulate the chemical compound of intracellular Ca2+|
    US9775882B2|2007-09-20|2017-10-03|Medtronic, Inc.|Medical devices and methods including polymers having biologically active agents therein|
    WO2009137631A2|2008-05-07|2009-11-12|Wintherix Llc|Methods for identifying compounds that affect expression of cancer-related protein isoforms|
    WO2009137630A1|2008-05-07|2009-11-12|Wintherix Llc|Methods for identifying compounds that modulate wnt signaling in cancer cells|
    EP2309993A1|2008-06-25|2011-04-20|US Worldmeds LLC|Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery|
    WO2010005507A1|2008-06-30|2010-01-14|Afgin Pharma, Llc|Topical regional neuro-affective therapy|
    WO2010022140A1|2008-08-19|2010-02-25|Knopp Neurosciences, Inc.|Compositions and methods of using -pramipexole|
    MY157445A|2008-08-27|2016-06-15|Calcimedica Inc|Compounds that modulate intracellular calcium.|
    EP2165706A1|2008-09-18|2010-03-24|BioAlliance Pharma|Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.|
    US20100158905A1|2008-12-19|2010-06-24|Nuon Therapeutics, Inc.|Combination therapy of arthritis with tranilast|
    ES2559029T3|2009-04-24|2016-02-10|Tissue Tech, Inc.|Compositions containing the HC.HA complex and methods of use thereof|
    WO2010148409A1|2009-06-19|2010-12-23|Knopp Neurosciences, Inc.|Compositions and methods for treating amyotrophic lateral sclerosis|
    US8329734B2|2009-07-27|2012-12-11|Afgin Pharma Llc|Topical therapy for migraine|
    US7718662B1|2009-10-12|2010-05-18|Pharmacyclics, Inc.|Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase|
    EP2329849B1|2009-11-18|2015-04-29|Galderma Research & Development|Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder|
    US8394800B2|2009-11-19|2013-03-12|Galderma Laboratories, L.P.|Method for treating psoriasis|
    WO2011097594A2|2010-02-08|2011-08-11|Kinagen, Inc.|Therapeutic methods and compositions involving allosteric kinase inhibition|
    KR20180032686A|2010-03-24|2018-03-30|아미텍 테러퓨틱 솔루션즈 인크|Heterocyclic compounds useful for kinase inhibition|
    MX2012010823A|2010-03-26|2012-10-10|Galderma Res & Dev|Improved methods and compositions for safe and effective treatment of telangiectasia.|
    EP2552449B1|2010-03-26|2017-04-19|Galderma Research & Development|Compositionscomprising brimonidine for the treatment of erythema|
    DK2557924T3|2010-04-13|2019-09-23|Relmada Therapeutics Inc|DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2 ', 6'-PIPECOLOXYLIDEIDE AND PROCEDURE FOR THEIR USE|
    WO2011130689A1|2010-04-15|2011-10-20|Tracon Pharmaceuticals, Inc.|Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors|
    AU2011248579A1|2010-04-27|2012-11-29|Calcimedica, Inc.|Compounds that modulate intracellular calcium|
    PL2563776T3|2010-04-27|2017-01-31|Calcimedica Inc|Compounds that modulate intracellular calcium|
    WO2011135530A2|2010-04-28|2011-11-03|Kimberly-Clark Worldwide, Inc.|Device for delivery of rheumatoid arthritis medication|
    DK2563453T3|2010-04-28|2017-05-22|Kimberly Clark Co|Nano-patterned medical device with improved cellular interaction and process for its preparation|
    EP2563455A4|2010-04-28|2014-02-19|Kimberly Clark Co|Method for increasing permeability of an epithelial barrier|
    AU2011246880B2|2010-04-28|2015-10-29|Sorrento Therapeutics, Inc.|Medical devices for delivery of siRNA|
    ES2688072T3|2010-05-11|2018-10-30|Mallinckrodt Ard Ip Limited|ACTH for the treatment of amyotrophic lateral sclerosis|
    EA031737B1|2010-06-03|2019-02-28|Фармасайкликс, Инк.|USE OF INHIBITORS OF BRUTON'S TYROSINE KINASEFOR TREATING LEUKEMIA AND LYMPHOMA|
    AU2011293201B2|2010-08-27|2015-11-05|Calcimedica Inc.|Compounds that modulate intracellular calcium|
    US8623409B1|2010-10-20|2014-01-07|Tris Pharma Inc.|Clonidine formulation|
    US8053427B1|2010-10-21|2011-11-08|Galderma R&D SNC|Brimonidine gel composition|
    EP2444068B2|2010-10-21|2017-12-06|Galderma S.A.|Brimonidine gel composition|
    US8796416B1|2010-10-25|2014-08-05|Questcor Pharmaceuticals, Inc|ACTH prophylactic treatment of renal disorders|
    CN103313710A|2010-11-02|2013-09-18|积水医疗株式会社|Patch|
    MY175521A|2011-01-07|2020-07-01|Allergan Inc|Melanin modification compositions and methods of use|
    EP2665741B1|2011-01-10|2019-03-06|Invion, Inc|Use of beta-adrenergic inverse agonists for smoking cessation|
    US8696637B2|2011-02-28|2014-04-15|Kimberly-Clark Worldwide|Transdermal patch containing microneedles|
    WO2012149486A1|2011-04-28|2012-11-01|Tissuetech, Inc.|Methods of modulating bone remodeling|
    US9682044B2|2011-06-10|2017-06-20|Tissuetech, Inc.|Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof|
    KR102265775B1|2011-10-27|2021-06-16|소렌토 쎄라퓨틱스, 인코포레이티드|Transdermal delivery of high viscosity bioactive agents|
    CA2795586A1|2011-11-15|2013-05-15|Golden Biotechnology Corporation|Methods and compositions for treatment, modification and management of bone cancer pain|
    WO2013072763A2|2011-11-16|2013-05-23|Nometics Inc.|Non-sensitizing transdermal clonidine patch|
    US9512096B2|2011-12-22|2016-12-06|Knopp Biosciences, LLP|Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds|
    US20130172424A1|2011-12-30|2013-07-04|Golden Biotechnology Corporation|Methods and compositions for treating diabetes|
    US8377946B1|2011-12-30|2013-02-19|Pharmacyclics, Inc.|Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors|
    FR2987264A1|2012-02-23|2013-08-30|Golden Biotechnology Corp|METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER METASTASES|
    US10905656B2|2012-03-26|2021-02-02|Golden Biotechnology Corporation|Methods and compositions for treating arteriosclerotic vascular diseases|
    EP3838293A1|2012-07-11|2021-06-23|Tissuetech, Inc.|Compositions containing hc-ha/ptx3 complexes and methods of use thereof|
    US9895320B2|2012-09-28|2018-02-20|KM Transderm Ltd.|Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer|
    US9512116B2|2012-10-12|2016-12-06|Calcimedica, Inc.|Compounds that modulate intracellular calcium|
    CN104968339B|2012-11-21|2019-06-11|国鼎生物科技股份有限公司|For treating the method and composition of neurodegenerative disease|
    JP6542128B2|2013-01-11|2019-07-10|コルセア ファーマ インコーポレイテッド|Treprostinil Prodrugs|
    US9505737B2|2013-01-11|2016-11-29|Corsair Pharma, Inc.|Treprostinil derivative compounds and methods of using same|
    TWI597061B|2013-02-20|2017-09-01|國鼎生物科技股份有限公司|Methods and compositions for treating leukemia|
    US9662313B2|2013-02-28|2017-05-30|Knopp Biosciences Llc|Compositions and methods for treating amyotrophic lateral sclerosis in responders|
    US10232018B2|2013-03-14|2019-03-19|Mallinckrodt Ard Ip Limited|ACTH for treatment of acute respiratory distress syndrome|
    EP2999444A4|2013-05-20|2016-10-12|Mylan Inc|Transdermal extended dosing of pramipexole for neurological disorders|
    US9468630B2|2013-07-12|2016-10-18|Knopp Biosciences Llc|Compositions and methods for treating conditions related to increased eosinophils|
    WO2015006708A1|2013-07-12|2015-01-15|Knopp Biosciences Llc|Treating elevated levels of eosinophils and/or basophils|
    AU2014306683B2|2013-08-13|2017-10-12|Knopp Biosciences Llc|Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders|
    ES2871556T3|2013-08-13|2021-10-29|Knopp Biosciences Llc|Compositions and methods for the treatment of chronic urticaria|
    WO2015054283A1|2013-10-08|2015-04-16|Calcimedica, Inc.|Compounds that modulate intracellular calcium|
    JP6345786B2|2013-12-05|2018-06-20|ファーマサイクリックス エルエルシー|Inhibitors of Breton-type tyrosine kinase|
    US20160367520A1|2014-02-10|2016-12-22|Patara Pharma, LLC|Mast cell stabilizers for lung disease treatment|
    HUE047319T2|2014-02-10|2020-04-28|Respivant Sciences Gmbh|Mast cell stabilizers treatment for systemic disorders|
    WO2015164213A1|2014-04-23|2015-10-29|The Research Foundation For The State University Of New York|A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith|
    TW201603818A|2014-06-03|2016-02-01|組織科技股份有限公司|Compositions and methods|
    JP6561109B2|2014-07-16|2019-08-14|コルセア ファーマ インコーポレイテッド|Treprostinil derivative compound and method of using the same|
    CA2958747A1|2014-08-15|2016-02-18|Tepha, Inc.|Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof|
    US9839644B2|2014-09-09|2017-12-12|ARKAY Therapeutics, LLC|Formulations and methods for treatment of metabolic syndrome|
    US10485893B2|2014-11-13|2019-11-26|Sarasota Medical Products, Inc.|Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof|
    US9359316B1|2014-11-25|2016-06-07|Concentric Analgesics, Inc.|Prodrugs of phenolic TRPV1 agonists|
    US10626521B2|2014-12-11|2020-04-21|Tepha, Inc.|Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof|
    US9555155B2|2014-12-11|2017-01-31|Tepha, Inc.|Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof|
    US10227333B2|2015-02-11|2019-03-12|Curtana Pharmaceuticals, Inc.|Inhibition of OLIG2 activity|
    MX2017011280A|2015-03-02|2018-06-27|Afgin Pharma Llc|Topical regional neuro-affective therapy with cannabinoids.|
    US10383816B2|2015-03-02|2019-08-20|Afgin Pharma, Llc|Topical regional neuro-affective therapy with cannabinoid combination products|
    CN107847526A|2015-05-20|2018-03-27|组织技术公司|For preventing the propagation of epithelial cell and the composition and method of the conversion of epithelium mesenchyma|
    US9643911B2|2015-06-17|2017-05-09|Corsair Pharma, Inc.|Treprostinil derivatives and compositions and uses thereof|
    US9394227B1|2015-06-17|2016-07-19|Corsair Pharma, Inc.|Treprostinil derivatives and compositions and uses thereof|
    EP3331522A1|2015-08-07|2018-06-13|Patara Pharma LLC|Methods for the treatment of mast cell related disorders with mast cell stabilizers|
    US10265296B2|2015-08-07|2019-04-23|Respivant Sciences Gmbh|Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders|
    EP3344254A1|2015-08-31|2018-07-11|Pharmacyclics LLC|Btk inhibitor combinations for treating multiple myeloma|
    WO2017147146A1|2016-02-23|2017-08-31|Concentric Analgesics, Inc.|Prodrugs of phenolic trpv1 agonists|
    JP2019516700A|2016-05-12|2019-06-20|ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン|ASH1L inhibitor and treatment method using the same|
    WO2017205534A1|2016-05-25|2017-11-30|Concentric Analgesics, Inc.|Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia|
    WO2017205762A1|2016-05-27|2017-11-30|Pharmacyclics Llc|Inhibitors of interleukin-1 receptor-associated kinase|
    WO2017205766A1|2016-05-27|2017-11-30|Pharmacyclics Llc|Inhibitors of interleukin-1 receptor-associated kinase|
    WO2017205769A1|2016-05-27|2017-11-30|Pharmacyclics Llc|Inhibitors of interleukin-1 receptor-associated kinase|
    US20180049994A1|2016-08-16|2018-02-22|Afgin Pharma, Llc|Topical regional neuro-affective therapy with caryophyllene|
    SG11201901679XA|2016-08-26|2019-03-28|Curtana Pharmaceuticals Inc|Inhibition of olig2 activity|
    EP3506893A4|2016-08-31|2020-01-22|Respivant Sciences GmbH|Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis|
    CN109803724A|2016-10-07|2019-05-24|瑞思皮万特科学有限责任公司|For treating the Cromoglycic acid composition of pulmonary fibrosis|
    CN110381930A|2016-12-05|2019-10-25|康赛制药公司|The percutaneous and transdermal administration of treprostinil and its salt|
    CN111542318A|2017-11-10|2020-08-14|密歇根大学董事会|ASH1L degradants and methods of treatment therewith|
    JP2021505600A|2017-12-07|2021-02-18|ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン|NSD family inhibitors and methods of treatment with them|
    TW202019887A|2018-07-27|2020-06-01|美商同心止痛劑股份有限公司|Pegylated prodrugs of phenolic trpv1 agonists|
    KR20220009373A|2019-03-15|2022-01-24|유니사이시브 테라퓨틱스 인코포레이티드|nicorandyl derivatives|
    CN111035627A|2020-01-09|2020-04-21|范小玲|Clonidine transdermal patch and preparation method thereof|
    JP2021011500A|2020-10-26|2021-02-04|コルセア ファーマ インコーポレイテッド|Treprostinil derivative compound and method of using the same|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/815,033|US4201211A|1977-07-12|1977-07-12|Therapeutic system for administering clonidine transdermally|
    [返回顶部]